CARM OTC
Carisma Therapeutics, Inc.
1W: +0.0%
1M: +0.0%
3M: -99.8%
YTD: -99.8%
1Y: -100.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±177.2%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.0001-1.27
Volume1,846
Avg Volume60,319
Beta1.31
Dividend—
Analyst Ratings
Company Info
CEOSaar Gill
Employees46
SectorHealthcare
IndustryBiotechnology
IPO Date2014-02-06
Websitecarismatx.com
3675 Market St.
Philadelphia, PA 19104
US
Philadelphia, PA 19104
US
484 899 0326
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Klichinsky Michael | M-Exempt | 56,982 | $0.11 | 2025-10-07 |
| Klichinsky Michael | S-Sale | 56,982 | $0.25 | 2025-10-07 |
| Klichinsky Michael | M-Exempt | 56,982 | $0.11 | 2025-10-07 |
| Klichinsky Michael | S-Sale | 119,347 | $0.26 | 2025-10-03 |
| Klichinsky Michael | S-Sale | 200,000 | $0.25 | 2025-10-02 |